148 related articles for article (PubMed ID: 17389325)
1. Helicobacter pylori eradication and L-dopa absorption in patients with PD and motor fluctuations.
Fiddian-Green RG
Neurology; 2007 Mar; 68(13):1085; author reply 1085. PubMed ID: 17389325
[No Abstract] [Full Text] [Related]
2. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations.
Pierantozzi M; Pietroiusti A; Brusa L; Galati S; Stefani A; Lunardi G; Fedele E; Sancesario G; Bernardi G; Bergamaschi A; Magrini A; Stanzione P; Galante A
Neurology; 2006 Jun; 66(12):1824-9. PubMed ID: 16801644
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of levodopa in patients with Parkinson disease and motor fluctuations depending on the presence of Helicobacter pylori infection.
Narożańska E; Białecka M; Adamiak-Giera U; Gawrońska-Szklarz B; Sołtan W; Schinwelski M; Robowski P; Madaliński MH; Sławek J
Clin Neuropharmacol; 2014; 37(4):96-9. PubMed ID: 24992088
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
5. Helicobacter pylori eradication for Parkinson's disease.
Rees K; Stowe R; Patel S; Ives N; Breen K; Clarke CE; Ben-Shlomo Y
Cochrane Database Syst Rev; 2011 Nov; (11):CD008453. PubMed ID: 22071847
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of gastric complications on levodopa treatment in Parkinson's disease.
Pfeiffer RF; Isaacson SH; Pahwa R
Parkinsonism Relat Disord; 2020 Jul; 76():63-71. PubMed ID: 32461054
[TBL] [Abstract][Full Text] [Related]
7. Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease.
Lee WY; Yoon WT; Shin HY; Jeon SH; Rhee PL
Mov Disord; 2008 Sep; 23(12):1696-700. PubMed ID: 18649391
[TBL] [Abstract][Full Text] [Related]
8. Should levodopa be used anymore?
Zegers de Beyl D
Acta Neurol Belg; 2002 Dec; 102(4):163-6. PubMed ID: 12534242
[TBL] [Abstract][Full Text] [Related]
9. Clinical spectrum of levodopa-induced complications.
Aquino CC; Fox SH
Mov Disord; 2015 Jan; 30(1):80-9. PubMed ID: 25488260
[TBL] [Abstract][Full Text] [Related]
10. Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson's disease patients.
Pierantozzi M; Pietroiusti A; Sancesario G; Lunardi G; Fedele E; Giacomini P; Frasca S; Galante A; Marciani MG; Stanzione P
Neurol Sci; 2001 Feb; 22(1):89-91. PubMed ID: 11487216
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
Stocchi F; Marconi S
Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
[TBL] [Abstract][Full Text] [Related]
12. Levodopa in the early treatment of Parkinson's disease.
Murata M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
[TBL] [Abstract][Full Text] [Related]
13. Coadministration of hydroxysafflor yellow A with levodopa attenuates the dyskinesia.
Wang T; Duan SJ; Wang SY; Lu Y; Zhu Q; Wang LJ; Han B
Physiol Behav; 2015 Aug; 147():193-7. PubMed ID: 25914172
[TBL] [Abstract][Full Text] [Related]
14. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
[TBL] [Abstract][Full Text] [Related]
15. Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint.
Nyholm D; Askmark H; Aquilonius SM
Ann Neurol; 2011 Feb; 69(2):424; author reply 425. PubMed ID: 21387388
[No Abstract] [Full Text] [Related]
16. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
[TBL] [Abstract][Full Text] [Related]
17. Effects of Helicobacter pylori on Levodopa Pharmacokinetics.
Nyholm D; Hellström PM
J Parkinsons Dis; 2021; 11(1):61-69. PubMed ID: 33164946
[TBL] [Abstract][Full Text] [Related]
18. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P
J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
[TBL] [Abstract][Full Text] [Related]
19. [Physiopathology of the dyskinesias induced by L-dopa].
Grandas F; López-Ariztegui N
Rev Neurol; 1997 Aug; 25 Suppl 2():S151-6. PubMed ID: 9280682
[TBL] [Abstract][Full Text] [Related]
20. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
Mazzella L; Yahr MD; Marinelli L; Huang N; Moshier E; Di Rocco A
Parkinsonism Relat Disord; 2005 May; 11(3):151-5. PubMed ID: 15823479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
